Navigating An Uncertain Regulatory Environment For mRNA-Based Products

If you're developing an mRNA-based therapeutic outside the vaccine space, the regulatory picture is less clear than you might expect. As of March 2024, neither the FDA nor the European Medicines Agency (EMA) has issued chemistry, manufacturing, and control (CMC)-specific guidelines for mRNA products. What exists is fragmented: the FDA's 2018 guidance on liposome drug products, the 2022 nanomaterials guidance, and the United States Pharmacopeia's (USP) April 2023 draft analytical procedures for mRNA vaccine quality. Useful, but none of it written with oncology, HIV, or rare disease mRNA therapies in mind.

In Europe, the classification question alone is complicated. Depending on intended use, your product may fall under Gene Therapy Medicinal Products (GTMPs) or Somatic Cell Therapy Medicinal Products (sCTMPs) within the Advanced Therapy Medicinal Products (ATMPs) framework, each carrying different controls and risk requirements.

The practical implication: you can't wait for guidance to catch up. Early scientific advice meetings with regulators, particularly with FDA's Center for Biologics Evaluation and Research (CBER), give your review division early familiarity with your product and process. That preparation matters. Bringing a Contract Development and Manufacturing Organization (CDMO) with direct mRNA regulatory experience into those conversations can sharpen the questions you ask and the feedback you receive.

Access the full analysis to build a regulatory engagement strategy that keeps your mRNA program on track through every clinical milestone.